In vivo synergism of roxithromycin (RU 965) and interferon against Toxoplasma gondii.
We investigated the activity of roxithromycin (RU 965) and gamma interferon alone and in combination in a murine model of toxoplasmic encephalitis. Roxithromycin at a dosage of 35 or 50 mg per mouse per day decreased mortality. Gamma interferon alone significantly prolonged time to death. When combined, the two agents were remarkably synergistic.
D000821:Animal Feed; D000818:Animals; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D004357:Drug Synergism; D004359:Drug Therapy, Combination; D004660:Encephalitis / Q000188:drug therapy*; D005260:Female; D007371:Interferon-gamma / Q000627:therapeutic use*; D007933:Leucomycins / Q000627:therapeutic use*; D051379:Mice; D014124:Toxoplasmosis, Animal / Q000188:drug therapy*
D000900:Anti-Bacterial Agents; D007933:Leucomycins; D007371:Interferon-gamma